AP NEWS
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Globe Newswire
This content is a press release from our partner Globe Newswire. The AP newsroom and editorial departments were not involved in its creation.

miRagen Therapeutics to Present a Corporate Overview at the 29th Annual Oppenheimer & Co. Healthcare Conference

March 6, 2019

BOULDER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that William S. Marshall, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Oppenheimer & Co. 29th Annual Healthcare Conference, taking place March 19-20 in New York City.

Oppenheimer & Co. 29th Annual Healthcare Conference Date: Wednesday, March 20 Time: 8:35am Eastern Time Webcast: https://www.veracast.com/webcasts/opco/healthcare2019/12203596823.cfm

The presentation will be webcast live and may also be accessed by visiting the “Investors & Media” section of the Company’s web site at www.miragen.com. A replay of the webcast will be available for 90 days after the event.

About miRagen Therapeutics, Inc.miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has three clinical stage product candidates, cobomarsen (MRG-106), remlarsen (MRG-201), and MRG-110. miRagen’s clinical product candidate for the treatment of certain cancers, cobomarsen, is an inhibitor of microRNA-155, which is found at abnormally high levels in malignant cells of several blood cancers, as well as certain cells involved in inflammation. miRagen’s clinical product candidate for the treatment of pathological fibrosis, remlarsen, is a replacement for microRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as systemic sclerosis. MRG-110, an inhibitor of microRNA-92, is being developed under a license and collaboration agreement with Servier for the treatment of heart failure and other ischemic disease. In addition to these programs, miRagen is developing a pipeline of preclinical product candidates. The goal of miRagen’s translational medicine strategy is to progress rapidly to first-in-human studies once it has established the pharmacokinetics, pharmacodynamic, safety and manufacturability of the product candidate in preclinical studies. For more information, please visit www.miragen.com.

For information on clinical trials please visit www.clinicaltrials.gov.

Investor/Media Contact: Adam Levy Chief Business Officer (720) 407-4595 alevy@miragen.com